Scalper1 News
Biotech stocks took another beating Friday, led by Gilead Sciences as concerns grew about its blockbuster drug Sovaldi. Gilead (GILD) tumbled 4% to close at 68.55, a four-month low. The stock was already hit the previous Friday on word of a congressional inquiry into its high price for Sovaldi, launched in December as a revolutionary treatment for hepatitis C. This Friday, IMS Health prescription data for the week ended March 21 Scalper1 News
Scalper1 News